ArticleJournal of pharmaceutical health care and sciences2025
Isosakuranetin ameliorates hypertension in rats induced by L-NAME.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is a major global health problem that often develops without noticeable symptoms. Current treatments and complementary approaches focus on improving endothelial function and enhancing nitric oxide (NO) production to promote vasodilation and lower blood pressure. Isosakuranetin, a flavanone found in Chromolaena odorata leaves, has shown potential antihypertensive properties. This study aimed to investigate the effects of isosakuranetin on L-N
methodsThis study investigated the antihypertensive effects of the flavanone isosakuranetin in male Wistar rats (n = 8 per group). Hypertension was induced by L-NAME, a nitric oxide synthase inhibitor, for four weeks, followed by treatment with isosakuranetin (10, 20, or 40 mg/kg) or enalapril (10 mg/kg) for an additional two weeks. Systolic blood pressure (SBP), heart rate, and body weight were monitored weekly. After six weeks, the effects of isosakuranetin on NO level and oxidative stress were assessed using the Griess reaction, 2',7'-dichlorofluorescein diacetate (DCF-DA), and superoxide dismutase (SOD) activity assays.
resultsThe results demonstrated that the SBP was significantly reduced in the isosakuranetin treatment group when compared to the hypertensive group. Additionally, isosakuranetin treatment significantly restored plasma nitrate/nitrite levels and showed the potential to reduced oxidative stress, as indicated by the decrease in reactive oxygen species (ROS) levels and a significant increase in SOD activity.
conclusionThese findings suggest that isosakuranetin is a promising natural compound for managing hypertension, demonstrating its potential for clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.